Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

by · The Cerbat Gem

Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) has earned an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $37.25.

A number of analysts recently issued reports on the stock. Zacks Research raised shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a report on Thursday, August 20th. BTIG Research lifted their price objective on shares of Alto Neuroscience from $28.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, August 13th. HC Wainwright upped their price objective on shares of Alto Neuroscience from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, August 17th. Wall Street Zen lowered shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research note on Saturday, September 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, July 29th.

Check Out Our Latest Report on ANRO

Alto Neuroscience Trading Down 2.1%

Shares of NYSE:ANRO opened at $26.62 on Tuesday. Alto Neuroscience has a 12-month low of $3.77 and a 12-month high of $37.48. The company has a market capitalization of $1.04 billion, a PE ratio of -11.00 and a beta of 1.13. The business has a 50 day moving average of $31.19 and a two-hundred day moving average of $26.01. The company has a current ratio of 14.85, a quick ratio of 14.85 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08. As a group, analysts forecast that Alto Neuroscience will post -2.68 EPS for the current year.

Hedge Funds Weigh In On Alto Neuroscience

Hedge funds have recently bought and sold shares of the business. Commodore Capital LP grew its holdings in Alto Neuroscience by 49.4% in the first quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock valued at $61,217,000 after purchasing an additional 900,000 shares during the period. Perceptive Advisors LLC raised its stake in shares of Alto Neuroscience by 12.6% during the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock worth $45,182,000 after buying an additional 225,500 shares during the period. Spruce Street Capital LP lifted its position in shares of Alto Neuroscience by 494.7% during the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after buying an additional 1,102,366 shares in the last quarter. Affinity Asset Advisors LLC purchased a new position in shares of Alto Neuroscience during the 1st quarter valued at approximately $11,240,000. Finally, Jennison Associates LLC acquired a new stake in Alto Neuroscience in the 1st quarter valued at $8,687,000.

About Alto Neuroscience

(Get Free Report)

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with neuropsychiatric disorders. The company combines clinical data, biological measurements and digital assessments to identify patient characteristics that may help predict treatment response and guide the development of more targeted therapies.

Alto’s pipeline has included investigational treatments for conditions such as major depressive disorder and schizophrenia.

Further Reading